ClinicalTrials.gg
RecruitingNCT06072924Updated Sep 4, 2026

K01 Impacts of Lingual Endurance Exercise

An interventional study of Isotonic Endurance Exercise and Sham Exercise in Dysphagia, Dysphagia, Oropharyngeal and Ischemic Stroke, sponsored by University of Cincinnati. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by University of Cincinnati · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether a tongue endurance exercise program can improve swallowing function in adults with dysphagia after a stroke. It also aims to explore how this exercise may affect brain structure and connectivity involved in swallowing. The main questions it aims to answer are:

Primary Aim: Does lingual endurance exercise improve swallowing function compared to a sham therapy? Secondary Aim: Does lingual endurance exercise lead to changes in brain structure or neuroplasticity, as measured by MRI?

Researchers will compare a group receiving tongue endurance exercises to a sham therapy group to see whether the treatment improves tongue function, swallowing.

Participants will:

  • Complete a baseline swallowing assessment and MRI
  • Be randomly assigned to either the lingual exercise or sham therapy group
  • Complete 8 weeks of home-based tongue exercise therapy
  • Return for follow-up swallowing assessments
  • A subgroup of participants will complete a pre-treatment and post-treatment MRI.
Read the detailed description

This randomized, controlled clinical trial investigates the efficacy of a 8-week lingual endurance exercise program in adults with dysphagia following stroke. The study uses a two-arm, parallel-group design with participants randomized to either a lingual endurance exercise group or a sham therapy control group. Both interventions are delivered using a lingual manometer, which participants use at home under monitored conditions.

The primary aim is to evaluate changes in oral-phase swallowing physiology using the Modified Barium Swallow Impairment Profile (MBSImP) Oral Total Score, as assessed through video-fluoroscopic swallowing study (VFSS).

An exploratory aim will assess potential neuroplasticity associated with lingual endurance exercise using multimodal neuroimaging. Participants who meet MRI eligibility criteria undergo pre- and post-intervention imaging, including diffusion tensor imaging (DTI) to assess white matter integrity, high-resolution structural imaging for cortical thickness estimation, and functional MRI (task-based and resting state). Data will be used to evaluate intervention-related changes in regions associated with swallowing motor control and sensory integration.

This study also supports the investigator's training in clinical trial methodology, swallowing outcomes analysis, and neuroimaging techniques, and will inform a future, fully powered efficacy trial.

02

Conditions studied

  • Dysphagia
  • Dysphagia, Oropharyngeal
  • Ischemic Stroke
  • Stroke

Keywords

  • swallowing trouble
  • difficulty swallowing
  • swallow rehab
03

In context

Deglutition Disorders

871 studies on the registry are indexed under Deglutition Disorders; 237 are open to participants now.

This study's planned enrollment of 70 is above the median of 60 across 578 interventional studies indexed under Deglutition Disorders.

Browse Deglutition Disorders studies →

Lead sponsor

University of Cincinnati is the lead sponsor of 324 studies on the registry; 42 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 15 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1) 3-6 months since most recent diagnosis of ischemic, confirmed from clinical imaging) with or without small hemorrhagic transformation (HI-1)
  • 2) English Speaking

Exclusion criteria

Exclusion Criteria:

  • 1) ≤18 years of age
  • 2) history of dysphagia prior to or after the stroke caused by any of the following conditions: gastrointestinal disease, traumatic brain injury, head and neck cancer, surgery involving the pharynx or larynx
  • 3) history of other neurological disease (i.e. multiple sclerosis, ALS, Parkinson's, dementia).

    5) 5) History of temporomandibular joint and muscle disorders (also known as TMJ).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Lingual Endurance Exercise

    The experimental exercise group will participate in 3 training sessions per day for 8 weeks. Endurance exercise will include completing isotonic endurance repetitions 3 times a day. Number of repetitions per session will be determined during baseline testing, and re-evaluated every 2 weeks, for each participant.

    Behavioral: Isotonic Endurance Exercise

  • Sham comparator
    Sham Exercise

    The sham control group will be instructed to press the lingual sensor 30 times at a very low-pressure threshold (approximately 1-15 kPa), which will be monitored weekly via device output sent to the study team to avoid use of excessive force that would qualify as exercise.

    Behavioral: Sham Exercise

Interventions

  • BehavioralIsotonic Endurance Exercise

    Pressing tongue against a pressure sensor at the set number of repetitions per session (individualized per participant) 3 times per day

  • BehavioralSham Exercise

    Pressing tongue against pressure sensor at a low threshold (1-15kPa) 30x/day

    Also known as: Learning group

06

What researchers measure

Primary outcomes

  1. Modified Barium Swallow Study Impairment Profile Oral Total (MBSImP OT Score)

    MBSImP is a validated, standardized tool for assessing oral, pharyngeal, and esophageal swallowing function. We will be using change in OT score (sum of components 1-6) as our primary outcome measure.

    Time frame: Change from Baseline (at the end of 8 weeks)

Secondary outcomes

  1. Pharyngeal Swallow Efficiency

    Measurements via the ASPEKT method (Analysis of Swallowing Physiology: Events, Kinematics, and Timing) will be analyzed to compared pre and post treatment swallow efficiency. The amount will be presented as a percent of anatomical C2-C4 Scalar. Higher percentile, in general indicated greater impairment, however these will be compared to published normative data for reference.

    Time frame: Change from Baseline (at the end of 8 weeks)

  2. Penetration Aspiration Scale (PAS) Scores

    8-point rating scale that is used to capture both degree and sensation of penetration and aspiration.

    Time frame: Change from Baseline (at the end of 8 weeks)

  3. Adherence

    number of repetitions attempted/total number of repetitions prescribed

    Time frame: At the end of 8 weeks

  4. Pharyngeal Swallow Safety

    Closure above the airway must be achieved for swallowing safety and in a timely manner. The ASPEKT method (Analysis of Swallow Physiology: Events, Kinematics and Timing) will be used to analyze changes of laryngeal vestibule closure pre and post treatment.

    Time frame: Change from Baseline (at the end of 8 weeks)

  5. Maximum Isometric Pressure imaging with video-fluoroscopy

    Maximum isometric press will be recorded in kPa and with recorded imaging using video-fluoroscopy. This will be collected pre- and post-therapy to determine any changes in oropharyngeal movements with a lingual press.

    Time frame: Change from Baseline (at the end of 8 weeks)

Other outcomes

  1. Change in fractional anisotropy (FA)

    Diffusion Tensor Imaging (DTI) has been the most common analysis framework that is used to analyze the signal from diffusion MRI (dMRI) to gather information about the properties of the underlying white matter.

    Time frame: Change from Baseline (at the end of 8 weeks)

  2. Change in cortical thickness

    Diffusion Tensor Imaging (DTI) has been the most common analysis framework that is used to analyze the signal from diffusion MRI (dMRI) to gather information about the properties of the underlying white matter.

    Time frame: Change from Baseline (at the end of 8 weeks)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — There is not a plan currently to share IPD with other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Aug 2027, 47 months after the start.

Of 288 non-industry interventional studies with no phase under Deglutition Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's planned 47 months is above that.

Counting every sponsor, half of 297 studies reached it within 21 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2023
First posted
Oct 10, 2023
StartActual
Sep 1, 2023
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2028
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06072924
Responsible party
Brittany Krekeler (Assistant Professor, University of Cincinnati) — Principal investigator
First posted
Oct 10, 2023
Start date
Sep 1, 2023
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Sep 4, 2026

Study contacts

Anna Hopkins, MS
Contact
hopkiak@ucmail.uc.edu
+1 513 558 4152
Rebecca Reinert
Contact
gibsonrk@ucmail.uc.edu
+1 513 558 1719
Brittany N Krekeler, PhD
principal investigator · University of Cincinnati

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion